Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study

By afschroeder • March 7, 2026

Yu HA, Tang KH, Markovets AA, Hartmaier R, Smith PE, Cho BC, De Langen AJ, Goldberg SB, Goldman JW, Le X, Iwama E, Cosaert J, Riess JW, Piotrowska Z. Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study. Clin Cancer Res. 2026 Mar 6. doi: 10.1158/1078-0432.CCR-25-4540. Epub ahead of print. PMID: 41790029.

Tags: Hematology/Oncology, Publications

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West[...]

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and[...]